Respiratory Distress Syndrome
Conditions
Keywords
infant, respiratory distress syndrome
Brief summary
Infants showing high local pulmonary inflammation diagnosted by respiratory distress syndrome usually need the second or more pulmonary surfactant and is easier to developing to Brochopulmonary. Cursurf is used worldwide in infants with respiratory distress syndrome, Budesonide is a glucocorticoid with a high local anti-inflammatory effect.Our hypothesis is Cursurf combined with Budesonide could reduced the need of Cursurf and incidence of Brochopulmonary dysplasia.
Interventions
DRUGBudesonide
Experimental: Cursurf and Budesonide The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation
Sponsors
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
No minimum to 12 Hours
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of respiratory distress syndrome
Exclusion criteria
* pneumothorax * surgical disease * major congenical defects
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| need of pulmonary surfactant | one month | The hypothesis is Cursurf/Budesonide could reduced the need of pulmonary surfactant |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the incidence of bronchopulmonary dysplasia | gestional age 36 weeks or later | the hypothesis is Cursurf and Budesonide could reduced the incidence of bronchopulmonary dysplasia. |
Other
| Measure | Time frame | Description |
|---|---|---|
| need of intubation | one month | The hypothesis is Cursurf/Budesonide could reduced the need of intubation |
Countries
China
Outcome results
None listed